t(9;22)(q34.1;q11.2)BCR::ABL1 (BCR-ABL+): This category comprises a subset of de novo AML developed in patients without a history of chronic myeloid leukemia (CML) and lacking recurrent genetic aberrations affecting the CEBPA or NPM1 gene, or cytogenetic alterations such as inv(16) or inv(3). The gene discussed is CEBPA; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.